@article{Blumenstock2025, 
author = {Kayce Blumenstock and Vandana Zaman and Camille Green and Narendra L. Banik and Azizul Haque},
title = {Emerging Roles of Fc Receptor-Like 1 in Immunotherapy of Diffuse Large B-Cell Lymphoma},
year = {2025},
journal = {BIOCELL},
volume = {49},
number = {10},
pages = {1859-1871},
keywords = {Fc receptor-like 1 (FCRL1), non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), immunoreceptor tyrosine-based activation motif (ITAM), immunoreceptor tyrosine-based inhibiting motif (ITIM), immunotherapy},
url = {https://www.sciopen.com/article/10.32604/biocell.2025.068773},
doi = {10.32604/biocell.2025.068773},
abstract = {Fc Receptor-Like 1 (FCRL1), a member of the FCRL family, contains two immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain and plays a critical role in B-cell biology. Its expression begins in pre-B-cells, dynamically shifts during B-cell development, and contributes to the regulation of human B-cell activation. Notably, FCRL1 is overexpressed in subsets of naive and memory B-cells, as well as in malignant B-cells, including those in diffuse large B-cell lymphoma (DLBCL), an aggressive and often treatment-resistant hematological malignancy. Among FCRL family members, FCRL1 stands out as a promising immunotherapeutic target due to its selective expression in malignant B-cells and its functional role in proliferation. Given the limited efficacy of current therapies for relapsed/refractory DLBCL, targeting FCRL1 could address an unmet clinical need by offering a novel, mechanism-based approach to modulate B-cell signaling and enhance anti-tumor immunity. This mini-review highlights the therapeutic potential of FCRL1-directed strategies, supporting their further exploration in preclinical models and future clinical trials for DLBCL and other B-cell malignancies.}
}